Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantern Pharma Inc
(NQ:
LTRN
)
3.130
+0.050 (+1.62%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lantern Pharma Inc
< Previous
1
2
3
4
5
6
Next >
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
March 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 19, 2024
Via
Benzinga
Recap: Lantern Pharma Q4 Earnings
March 18, 2024
Via
Benzinga
Lantern Pharma Earnings Preview
March 15, 2024
Via
Benzinga
Lantern Pharma: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
A Preview Of Lantern Pharma's Earnings
November 07, 2023
Via
Benzinga
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
March 18, 2024
LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
March 18, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Earnings Scheduled For March 18, 2024
March 18, 2024
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
March 15, 2024
From
Lantern Pharma Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
March 11, 2024
Via
Benzinga
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
March 11, 2024
From
Lantern Pharma Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
March 08, 2024
Via
Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
March 06, 2024
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 06, 2024
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.
Via
Benzinga
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
March 05, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
March 04, 2024
From
Lantern Pharma Inc.
Via
Business Wire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
March 04, 2024
Grand View Research says the global
Via
Talk Markets
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
February 20, 2024
Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
February 19, 2024
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
February 15, 2024
From
Lantern Pharma Inc.
Via
Business Wire
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
January 17, 2024
From
Lantern Pharma
Via
Business Wire
AI-Focused Drug Discovery Stocks Index Up 26% In December
December 29, 2023
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.
Via
Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 18, 2023
Via
Benzinga
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
December 17, 2023
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 3 Most Undervalued AI Penny Stocks to Buy in December
December 13, 2023
These AI penny stocks offer substantial returns to investors as the market continues to grow at a rapid pace.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
November 30, 2023
From
Lantern Pharma Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
November 09, 2023
Via
Benzinga
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
November 08, 2023
From
Lantern Pharma Inc.
Via
Business Wire
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
November 01, 2023
From
Lantern Pharma Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.